Vibativ (Telavancin HCl) Patent Expiration, LOE Window & CMS Spending

Vibativ (Telavancin HCl) by Apotex: FDA Orange Book core substance LOE 2027-01-01, 0 AB generics, $828K 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApotex
FDA Application & PathwayN022110 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2027-01-01
Last Listed Patent or Exclusivity Date2027-01-01
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$828K
2024 Medicare Part D Spend$553K
2024 Medicaid Spend$275K
Reported Wholesale Price Change (CA SB 17)7 WAC filings (max 21.8% 2-yr change)